PIK3CA and neoplasm: Currently, targeted therapy agents Crizotinib and Copanlisib approved for the treatment of tumours that harbour mutations in ROS1/MET/ALK and PIK3CA, while therapeutic agents for the other identified variants, including FGFR family, MYC, MET, and KRAS are currently under investigation in active and ongoing clinical trials.